Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hyman

Showing results (361-370 of 401) with videos related to

Pageof 41
Sort By:
Cancer Cell|January 10, 2018
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerRona Yaeger, Walid K Chatila, Marla D Lipsyc, et al.
JAMA Oncology|July 22, 2016
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing PlatformLuc G T Morris, Raghu Chandramohan, Lyndsay West, et al.
Cancer Treatment Reviews|May 21, 2019
Improving attribution of adverse events in oncology clinical trialsGoldy C George, Pedro C Barata, Alicyn Campbell, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
JAMA Oncology|July 7, 2018
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Semanti Mukherjee, Diana Mandelker, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Nature Communications|March 19, 2022
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancersEzra Y Rosen, Helen H Won, Youyun Zheng, et al.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
Cancer Discovery|January 12, 2020
Characteristics and Outcome of <i>AKT1</i> <sup>E17K</sup>-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic RegistryLillian M Smyth, Qin Zhou, Bastien Nguyen, et al.
Pageof 41

Showing results (361-370 of 401) with videos related to

Sort By:
Pageof 41
Cancer Cell|January 10, 2018
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerRona Yaeger, Walid K Chatila, Marla D Lipsyc, et al.
JAMA Oncology|July 22, 2016
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing PlatformLuc G T Morris, Raghu Chandramohan, Lyndsay West, et al.
Cancer Treatment Reviews|May 21, 2019
Improving attribution of adverse events in oncology clinical trialsGoldy C George, Pedro C Barata, Alicyn Campbell, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
JAMA Oncology|July 7, 2018
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Semanti Mukherjee, Diana Mandelker, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Nature Communications|March 19, 2022
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancersEzra Y Rosen, Helen H Won, Youyun Zheng, et al.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
Cancer Discovery|January 12, 2020
Characteristics and Outcome of <i>AKT1</i> <sup>E17K</sup>-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic RegistryLillian M Smyth, Qin Zhou, Bastien Nguyen, et al.
Pageof 41